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Anaemia, redistribution of iron, malnutrition and heightened systemic inflammation during HIV-2 
infection confer an increased risk of morbidity and mortality in HIV patients. We analysed 3 
information on iron status and inflammation from a randomised, double blind, controlled phase-III 4 
clinical trial in Lusaka, Zambia and Mwanza, Tanzania. Malnourished patients (n=1815) were 5 
recruited at referral to antiretroviral therapy (ART) into a two-stage nutritional rehabilitation 6 
programme, randomised to receive a lipid-based nutrient supplement with or without added 7 
micronutrients. Iron was included in the intervention arm during the second stage, given from 2-6 8 
weeks post-ART. Haemoglobin (Hb), serum C-reactive protein (CRP), serum ferritin and soluble 9 
transferrin receptor (sTfR) were measured at recruitment and 6 weeks post-ART. Multivariable 10 
linear regression models were used to assess the impact of the intervention, and the effect of 11 
reducing inflammation from recruitment to week 6, on Hb and iron status. There was no effect of 12 
the intervention on Hb, serum ferritin, sTfR or serum CRP. A one-log decrease of serum CRP from 13 
recruitment to week 6 was associated with a 1.81g/L increase in Hb (95% CI: 0.85, 2.76; p<0.001) 14 
and a 0.11 log decrease in serum ferritin (95% CI: -0.22, 0.03; p=0.012) from recruitment to week 15 
6. There was no association between the change in serum CRP and the change in sTfR over the 16 
same time period (p=0.78). In malnourished, HIV-infected adults receiving dietary iron, a reduction 17 
in inflammation in the early ART treatment period appears to be a precondition for recovery from 18 
anaemia.  19 
 20 
Introduction 21 
Independent risk factors for mortality amongst African patients starting antiretroviral therapy 22 
(ART) include anaemia(1), a failure to increase haemoglobin (Hb) within the first few months of 23 
ART(2), and malnutrition, represented by body mass index (BMI) < 18.5 kg/m2(3–5). Heightened 24 
systemic inflammation is a hallmark of both untreated and treated HIV infection(6), and higher 25 
levels of persistent inflammation despite treatment with ART(7) confer an increased risk of 26 
morbidity and mortality in HIV patients(8,9). Redistribution of iron during HIV infection can lead to 27 
increased iron sequestration in macrophages with an accompanying decline in iron available for 28 
tissue supply and erythropoiesis(7,10). This disordered iron metabolism has been associated with 29 
rapid progression of HIV(11–13), exacerbation of co-infections,(14) especially tuberculosis(15,16), and 30 
early death(17,18). Although ART is increasingly available, initiation of ART is associated with a 31 
high mortality: 17% of patients starting ART in sub-Saharan Africa die within one year and the 32 
majority within the first 3 months(19). Given the detrimental effects of anaemia, iron redistribution, 33 
malnutrition, and inflammation on early ART mortality, together with the fact that in Sub-Saharan 34 
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Africa the HIV disease burden remains vast(20) with a third of adults starting ART being 35 
malnourished in some African countries(3,21), the control of anaemia and normalisation of iron 36 
metabolism within this population remains a critical strategy for improving patient survival.  37 
Markers other than Hb are required to assess iron status. Serum ferritin can be used as a 38 
marker of body stores of iron(22) and soluble transferrin receptor (sTfR) to estimate tissue iron 39 
demand(23).  The determination of iron status in the presence of inflammation is notoriously 40 
challenging(24), with as yet no internationally agreed methodology(25). It is well known that 41 
inflammation alters many markers of iron status, including increasing serum ferritin as an acute 42 
phase protein(25). sTfR is less affected by the inflammatory response and can therefore be used to 43 
distinguish anaemia of inflammation (with elevated serum ferritin and normal-to-elevated sTfR) 44 
from iron deficiency anaemia (with low serum ferritin and high sTfR)(25,26). However, iron 45 
deficiency and inflammation often co-exist, complicating assessment of iron status and needs. 46 
Measurement of the acute phase proteins C-reactive protein (CRP) and α1-acid glycoprotein (AGP) 47 
can assist interpretation of the iron biomarkers in order to separate those patients with 48 
inflammation-induced iron sequestration from those who are both sequestering iron and iron-49 
deficient(27).  Hepcidin, the peptide hormone regulating iron metabolism through influencing the 50 
absorption of dietary iron and how iron is distributed among different cell types, can also be 51 
measured to help elucidate the complex interplay between anaemia, iron status and immunity(28).  52 
There are currently many unanswered questions about the range and characteristics of 53 
disordered iron metabolism among malnourished, HIV-infected adults, the preferred iron-related 54 
biomarkers for assessing health risks, and the effect of oral iron supplementation on iron status and 55 
health. The common assumption that low Hb requires therapeutic correction through iron 56 
supplementation may be erroneous in HIV since supplementation can exacerbate the risk of co-57 
infections and hasten disease progression. Paradoxically it is high serum ferritin that predicts a 58 
worse outcome despite the association of anaemia and mortality(18). Controversy therefore remains 59 
as to what extent iron supplementation amongst HIV-patients affects infection rates and 60 
mortality(29). Some interventions supplementing iron to HIV-positive adults have reduced anaemia 61 
without increasing viral load(30,31); longer-term outcomes were not assessed. This creates a 62 
therapeutic dilemma for the clinician as to how HIV-infected patients with anaemia should be 63 
treated. Given the clear link between anaemia and early ART mortality, the existing knowledge 64 
gaps jeopardise the health and survival of thousands of malnourished HIV/AIDS patients. 65 
Our study uses a clinical trial amongst malnourished adults starting ART to assess three 66 
main research questions. Firstly, what effect does a nutritional intervention including iron have on 67 
iron status? Secondly, does any impact depend on the baseline iron status of patients? Thirdly, does 68 
inflammation have an independent effect on changes in iron status? We hypothesised that the 69 
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nutritional intervention would improve iron status, indicated by an increase in haemoglobin 70 
accompanied by no change or a slight decrease in sTfR; effects on sTfR would depend on whether 71 
the anaemia was due primarily to chronic disease which has little effect on sTfR or to iron 72 
deficiency which results in increased sTfR(25).  We expected overall serum ferritin results to be 73 
harder to predict: decreasing in the correction of anaemia of inflammation but increasing for the 74 
correction of iron deficiency.  We speculated that failing to normalise systemic inflammation after 75 
starting ART would attenuate any improvements.  76 
 77 
Subjects and Methods 78 
 79 
Study design 80 
The study analyses information on iron status and inflammation from a randomised, double 81 
blind, controlled phase-III clinical trial in Lusaka, Zambia and Mwanza, Tanzania: the Nutritional 82 
Support for Africans Starting Antiretroviral Therapy (NUSTART) Trial (registered on the Pan-83 
African Clinical Trials Register as PACTR201106000300631). Details of the trial are described in 84 
full elsewhere(32,33). In brief, the NUSTART trial was conducted between August 2011 and 85 
December 2013 to assess the effect of a fortified lipid-based nutrient supplement (LNS; prepared by 86 
Nutriset, Malauney, France) on survival of malnourished patients starting ART. This paper focuses 87 
on two secondary outcomes: markers of iron status and inflammation. A total of 1815 patients were 88 
recruited at the two sites, using inclusion criteria of >18 years, BMI<18.5 kg/m2, CD4 count<350 89 
cells/µl or stage 3 or 4 AIDS, ART-naïve apart from those who received ART during standard 90 
prevention of mother-to-child transmission regimens, and informed consent. Self-reported 91 
pregnancy was an exclusion criterion.  92 
The trial intervention was based on established protocols for managing severe malnutrition 93 
in young children involving two phases aimed at stabilisation and then rehabilitation(34). Figure 1 94 
summarizes the NUSTART design. The first phase took place between referral and 2 weeks post-95 
ART initiation. Participants were randomized to receive vitamins and minerals, without iron as is 96 
done for malnourished children, in low calorie (30 g containing ~150 kcal/day) LNS (low dose 97 
LNS-VM) in the intervention group versus LNS without the vitamins and minerals (low dose 98 
control LNS) in the control group. This phase aimed to stabilise metabolism before trying to 99 
promote weight gain during the second phase. The second phase involved a 4-week intervention, 100 
starting 2 weeks after ART initiation and continuing to 6 weeks post-ART. Participants in the 101 
intervention group received a higher calorie (250g containing ~1400kcal/day) LNS containing the 102 
same added vitamins and minerals as in phase 1 plus iron as sulphate (high dose LNS-VM). The 103 
control group received the high dose LNS without the added vitamins, minerals, or iron (high dose 104 
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control LNS). Vitamin and mineral levels in both the high and low dose LNS-VM were mostly set 105 
at 3 times the UK recommended nutrient intakes (RNI) for adult women(35) with the exception of 106 
iron which was only in the second stage, high dose LNS and only at one RNI (14.7 mg/day) 107 
(nutritional composition details in Supplementary Material Table 1).  108 
The interval between referral for ART and starting ART was based on the individual 109 
patient’s readiness to start life-long drug treatment and practices of the different clinics from which 110 
the study recruited patients. Study personnel were not involved in deciding when to initiate ART 111 
and the duration of phase 1 reflects routine practice in these populations at the time. The median 112 
interval between referral for ART and starting ART for both arms was 21 days, (interquartile range 113 
[IQR] 15, 30). 55.4% of patients went on to take the ART regime Tenofovir (TDF)/ Emtricitabine 114 
(FTC)/ Efavirenz  (EVF), 16.0% took Zidovudine  (AZT)/ Lamivudine  (3TC)/ Nevirapine (NVP), 115 
9.2% took AZT/ 3TC/ EVF, 4.3% took TDF/ FTC/ NVP, 3.6% were on another regime and 11.5% 116 
had no ART regime information(32). 117 
The Data Safety and Monitoring Board (DSMB) statistician conducted the randomisation 118 
using 16 computer-generated blocks stratified by site. The contents of the LNS packets were 119 
assigned an allocation code (letters A to H), known only to the DSMB statistician and Nutriset, 120 
which were linked to study ID numbers using a randomisation code. This randomisation code was 121 
only known to the DSMB statistician and site-based pharmacists, none of whom had direct patient 122 
contact. The LNS and LNS-VM packets were delivered by Nutriset in lots assigned by allocation 123 
code. Clinic pharmacists labelled packets with study ID numbers as packets were dispensed. Clinic 124 
nurses (with no access to the allocation or randomisation code) then recruited eligible participants to 125 
the study using sequential IDs.  126 
 127 
Blood collection 128 
Patients were seen weekly from referral for ART until the ART initiation visit, then at 2, 6, 8, and 129 
12 weeks after starting ART. They were asked at each follow-up whether they were taking iron 130 
supplements in addition to the study supplement. Haemoglobin (Hb) and serum CRP were 131 
measured for all patients, whilst serum ferritin and sTfR were analysed on one fifth of the patients, 132 
referred to as the iron marker subsample and chosen systematically for every patient ID divisible by 133 
5. Haemoglobin was measured at recruitment and at 6 weeks post-ART. Iron markers and CRP 134 
were measured in serum from the recruitment and 6 weeks post-ART samples which were stored at 135 
-80ºC until batched analysis. The flow of participants included in the iron marker subsample from 136 
identification to analysis at baseline and week 6 is shown in Figure 2.  137 
 138 
Iron and inflammatory marker analysis 139 
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Hb levels were analysed by a portable haemoglobinometer (Hemocue®; Angelholm, Sweden) on 140 
fingerstick capillary blood samples from all patients. Anaemia severity cut-offs followed standard 141 
World Health Organisation categorisations(36). Mild anaemia was defined as Hb <120 g/L for 142 
women and <130 g/L for men. Moderate and severe anaemia categories used the same cut-offs for 143 
both sexes, defined as <110 g/L and <80 g/L respectively.  144 
Serum ferritin was measured by ELISA (AssayPro Human Ferritin ELISA Kit, Catalogue 145 
No. EF2003-1; St. Charles, MO, USA). The intra-assay and inter-assay coefficients of variability 146 
(CVs), respectively, were 2% and 7% in Mwanza and 5% and 23% in Lusaka. sTfR was measured 147 
by ELISA (Quantikine® IVD® Human sTfR Immunoassay, Ref DTFR1, R&D Systems, Inc. 148 
Minneapolis, USA). The intra-assay and inter-assay CVs were 2% and 4% in Mwanza and 3% and 149 
13% in Lusaka. Serum CRP was analysed by ELISA (AssayPro, St. Charles, MO, USA). The intra-150 
assay and inter-assay CVs were 3% and 37% in Mwanza and 6% and 32% in Lusaka. For all 151 
analytes values over the upper range of the standard curve were set to the top standard multiplied by 152 
the dilution factor. For all assays plates with poor precision were re-run. 153 
 154 
Sample size 155 
The original trial sample size was powered on the primary outcome (mortality). Our one in five 156 
subsample for the iron markers was sufficient to detect an inter-group difference of 0.35 standard 157 
deviations using 90% power. 158 
 159 
Data analysis  160 
Continuous variables were assessed for normality using normal probability plots and visual 161 
inspection of histograms. Hb and sTfR approximated a normal distribution and remained on the 162 
linear scale. Serum CRP and serum ferritin were skewed to the right and natural log-transformed. 163 
We considered using correction factors for ferritin derived from the methodology suggested by 164 
Thurnham et al.(27); however, since our population was extremely malnourished, and exhibited high 165 
levels of inflammation with very deranged iron metabolism, it was unclear whether correction 166 
factors derived from less ill populations were appropriate. We decided instead to simply adjust for 167 
CRP in regression analyses as has been done elsewhere(37).  168 
We compared baseline characteristics of those in the smaller sub-sample containing data on 169 
sTfR and serum ferritin (n=353) with those not in the sub-sample (n=1462) to assess the 170 
generalizability to the whole sample. The chi-squared test was used to compare proportions, 171 
independent t-tests to compare means of normally distributed data, and the Wilcoxon-Mann-172 
Whitney test to compare medians of non-parametric data. Sample sizes of all further analyses were 173 
set by the number of available samples at 6 weeks post-ART.  174 
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A variable was created to summarise the frequency of taking iron supplements in addition to 175 
the study supplement over the follow-up period; this was categorised as never consumed (62%), 176 
reported consumed at one follow-up (19%) and reported consumed at two or more follow-up visits 177 
(19%). We assessed the within-subject changes in markers of iron status and inflammation between 178 
baseline and week 6 by intervention arm using paired t-tests.  179 
For our first objective assessing the effect of the intervention on iron marker status at week 6 180 
we used multivariable linear regression. The first model adjusted only for the baseline value of the 181 
iron marker being assessed, the second model additionally adjusted for serum CRP at week 6 given 182 
our hypothesis that inflammation would affect iron markers, and the third model further adjusted for 183 
sex, site and being on TB treatment at recruitment as binary variables; taking iron supplements in 184 
addition to the study supplement as a categorical variable; and baseline BMI, age, CD4 count and 185 
length of time taken from recruitment to starting ART as continuous variables.  186 
For our second objective we repeated the third (fully adjusted) model analysis stratified by 187 
baseline values of the iron markers to determine whether these modified the effect of the 188 
intervention. We used a binary Hb category: normal Hb and mild anaemia vs. those with moderate 189 
and severe anaemia. Due to lack of internationally agreed cut-offs for serum ferritin and sTfR, as 190 
well as the specific context of our malnourished sample with heightened systemic inflammation, we 191 
divided these variables into two groups using the median value to create binary categories. We 192 
chose binary categories rather than continuous measures since we felt this would provide a more 193 
accessible way of interpreting overall trends that may have physiological significance. The test for 194 
interaction between the baseline iron marker category and intervention arm used a likelihood ratio 195 
test between the multivariable linear regression models with and without the interaction term. 196 
For our third objective we assessed to what extent inflammation was driving the changes in 197 
our iron markers independently of the intervention.  We investigated interrelations among the iron 198 
markers and serum CRP using Pearson correlation matrices. We then created a multiple linear 199 
regression model exploring the association between change in iron marker from baseline to week 6 200 
with change in serum CRP over the same timeframe, adjusting for trial arm, sex, site and being on 201 
TB treatment at recruitment as binary variables; taking iron supplements in addition to the study 202 
supplement as a categorical variable; and baseline BMI, age, CD4 count and length of time taken 203 
from recruitment to starting ART as continuous variables. 204 
Stata version 13.1 (StataCorp, College Station, TX, USA) was used for all analyses. 205 
 206 
Ethical considerations. This study was conducted according to the guidelines laid down in the 207 
Declaration of Helsinki. All NUSTART trial procedures, including the collection and analysis of 208 
the iron markers, were approved by the ethics committee of the London School of Hygiene and 209 
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Tropical Medicine, the University of Zambia Biomedical Research Ethics Committee (reference 210 
number 009-01-11), and the National Institute for Medical Research, Tanzania. Written informed 211 




Detailed baseline characteristics of the 1815 patients recruited are published elsewhere(32). In 216 
summary, one-third had BMI <16 kg/m2 and mean (SD) age was 35.8 (9.4) years. Only 10% of the 217 
patients were without anaemia at baseline, with two-thirds categorised as either moderately or 218 
severely anaemic. Table 1 shows the baseline characteristics for the subsample assessed for iron 219 
markers (n=353). Mean (SD) baseline Hb was lower amongst those in the iron marker sub-sample 220 
compared to those not included (93 (23) g/L vs. 96 (23) g/L, p=0.012). Median (IQR) serum CRP 221 
was higher amongst those in the sub-sample compared to those not included (71 (18,160) mg/L vs. 222 
57 (13,155) mg/L, p=0.004). Patient baseline characteristics in the iron subsample were very similar 223 
in the two treatment arms (Table 1), as was the case for the whole sample(32).  224 
In the control group from baseline to week 6 post-ART, patients gained a mean of 3 g/L Hb 225 
(p=0.029, n=369), decreased their serum ferritin by 100 μg/L (p=0.021, n=89), increased their sTfR 226 
by 4 nmol/L (p=0.045, n=101), but experienced no overall change in CRP levels (p=0.08, n=407) 227 
(Table 2). The intervention group displayed similar trends: patients gained a mean of 6g/L Hb 228 
(p=<0.001, n=383), decreased their serum ferritin by 141 μg/L (p=0.004, n=76), increased their 229 
sTfR by 4 nmol/L (p=0.030, n=85), and also experienced no overall change in CRP levels (p=0.36, 230 
n=431). There was no effect of the vitamins and minerals added to the intervention LNS on Hb, 231 
serum ferritin, sTfR or serum CRP in any of the three statistical models (Table 3). Note that sample 232 
sizes in Table 3, which used various adjusted models, were restricted to the patients who had no 233 
missing data in all the variables we adjusted for and therefore differ to those seen in Table 2, which 234 
used unadjusted data. 235 
Table 4 shows to what extent the intervention effect differed for patients based on their 236 
baseline iron marker category. The coefficient shows the change in week 6 iron marker associated 237 
with the intervention in comparison to the control within the baseline iron marker category strata. 238 
There was no evidence that the impact of the intervention on Hb at week 6 was affected by baseline 239 
iron marker category (p values >0.18 for interaction tests). Amongst those with moderate and 240 
severe anaemia at baseline, the intervention was associated with a decrease in 0.40 of log serum 241 
ferritin at week 6 (p=0.023).  However, evidence for an overall interaction between the intervention 242 
and baseline Hb on log serum ferritin was weak (p=0.12). There was no evidence of any interaction 243 
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between the intervention and baseline iron marker categories on sTfR at week 6 (p values >0.52 for 244 
interaction tests).  245 
At both baseline and week 6, Hb was negatively correlated with serum CRP, serum ferritin 246 
was positively associated with serum CRP and there was no correlation between sTfR with serum 247 
CRP (Table 5). At both time points sTfR was negatively correlated with Hb and serum ferritin. 248 
Serum ferritin was not correlated with Hb at baseline, but showed a weak positive correlation at 249 
week 6. 250 
Table 6 shows the associations between changes in serum CRP and changes in iron markers. 251 
A decrease in one-log of serum CRP from baseline to week 6 was associated with an increase of 252 
1.81g/L of Hb (95% CI: 0.85, 2.76; p<0.001) and a decrease of 0.11 log of serum ferritin (95% CI: -253 
0.20, 0.03; p=0.012) from baseline to week 6. There was no association between the change in 254 
serum CRP and the change in sTfR over the same time period (p=0.78). 255 
 256 
Discussion 257 
We hypothesised that the two-stage nutritional intervention involving a stabilisation phase followed 258 
by the provision of iron together with other micronutrients would help reverse anaemia of chronic 259 
disease and improve iron deficiency anaemia among malnourished, HIV-infected adults in sub-260 
Saharan Africa. Contrary to expectations, our results show the intervention with fortified LNS-VM 261 
made no overall difference to Hb or any iron markers. Furthermore, there was no obvious sub-262 
group, defined by baseline anaemia, serum ferritin or sTfR, which demonstrated any clinically 263 
meaningful improvement from the intervention. Although there was weak evidence to suggest that 264 
the effect of the intervention on serum ferritin at week 6 was dependent upon baseline levels of Hb, 265 
the reduction in log serum ferritin was small and there was no concomitant improvement in Hb or 266 
reduction in sTfR in this sub group, suggesting this finding was of no clinical significance.  267 
In unadjusted correlation analyses between the iron markers and CRP it was not surprising that 268 
serum ferritin, being a positive acute phase protein, was positively correlated with CRP at both time 269 
points. The negative correlation of sTfR with Hb and serum ferritin was also to be expected, due to 270 
sTfR being a marker of tissue iron deficiency and, more specifically, the requirement of iron for 271 
erythropoiesis(23). The linear regression model exploring the relationship between serum CRP and 272 
Hb suggested that reducing systemic inflammation between baseline and week 6 was associated 273 
with an increase of Hb over that time period. Iron metabolism involves a series of complex, tightly 274 
regulated mechanisms to ensure homeostasis, especially during infection or inflammation. Chief 275 
amongst these is the need to maintain iron tightly chaperoned in order to avoid oxidative damage 276 
and to limit its availability to pathogens(28). During HIV infection the chronic inflammation causes a 277 
10 
 
hepcidin-mediated redistribution of iron within the body, a process that becomes more pronounced 278 
as the HIV stage progresses(1,38). Up-regulated hepcidin inactivates ferroportin (the only iron-efflux 279 
channel in cells) causing decreased intestinal iron absorption as well as sequestration of iron in 280 
macrophages(28) thus blocking erythropoiesis. This leads to anaemia and possibly creates a niche for 281 
intra-cellular pathogens such as mycobacteria(14,39). Our results suggest that to reverse anaemia and 282 
normalise iron redistribution, the source of the innate immune activation first needs to be identified 283 
and addressed, and then only after systemic inflammation has been brought under control will an 284 
iron-containing nutritional intervention be likely to have an impact.   285 
Irrespective of whether the LNS was fortified with vitamins and minerals, it appeared that ART 286 
plus LNS improved haemoglobin levels and reduced serum ferritin. ART has been associated with a 287 
reduction in prevalence of anaemia in other studies(40–42), although some ART drugs, e.g. 288 
zidovudine(43) which was prescribed to 26% of NUSTART patients(33), have increased anaemia in 289 
some patients. However, in the NUSTART context the overall mean improvement of Hb and 290 
reduction of serum ferritin was modest. For there to have been enough of a functional improvement 291 
in the distribution and use of iron in the body we would have expected sTfR to at least remain stable 292 
if not drop, and yet in this context sTfR levels increased slightly. Irrespective of whether LNS was 293 
fortified with vitamins and minerals or not, the combination of LNS and ART for 6 weeks does not 294 
appear to sufficiently improve the iron profile of our patients or reduce their systemic inflammation. 295 
Our study carries several limitations. Patients in the sub-sample had lower baseline Hb and were 296 
more inflamed compared to those not in the sub-sample. This suggests the sub-sample patients were 297 
slightly sicker than those not included and may restrict our ability to extrapolate the results to the 298 
whole sample. Budget limitations precluded analysis of iron markers in the full cohort and analysis 299 
of results at other time points, for example, at the end of phase 1, as well as assessment of other 300 
potentially interesting markers such as hepcidin or AGP. Since there was no control group not 301 
receiving LNS (for ethical reasons) we are unable to separate the overall impact of ART and LNS 302 
on our outcomes.   303 
The level of iron fortification of the LNS during stage two was modest (1 RNI) in comparison to 304 
higher levels (usually 3 RNIs) of other micronutrients. This was a conservative approach to avoid 305 
potentially increasing the risks associated with higher serum ferritin stores. It would appear that the 306 
level of iron included in the fortified LNS was safe in this regard, since there was no overall 307 
increase in serum ferritin from the intervention. That said, we would recommend that iron dosage 308 
within fortified LNS not be increased in future research amongst similar populations before 309 
investigating the impact this modest fortification level has once inflammation has been successfully 310 
controlled. Further research is required: firstly, to determine whether non-nutritional interventions 311 
designed to reduce systemic inflammation are sufficient to correct anaemia of inflammation in HIV; 312 
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secondly, to assess whether a product with a different nutrient composition may also assist this 313 
process; and thirdly, to quantify the level of improvement in inflammation necessary before a 314 
nutritional intervention will improve iron deficiency anaemia.   315 
 316 
Conclusion 317 
Our large clinical trial of iron supplementation as part of a nutritional intervention showed no 318 
appreciable effect on Hb and iron metabolism, even when the majority of patients were anaemic at 319 
baseline. HIV-related inflammation resulting in disordered iron metabolism appears to severely 320 
attenuate the potential impact of receiving dietary iron in an intervention. Given the clear 321 
associations between anaemia, disordered iron metabolism and mortality amongst HIV-positive 322 
patients starting ART, it is of critical importance that strategies to reduce the level of systemic 323 
inflammation (going beyond the provision of ART) are investigated. Without the ability to control 324 
inflammation it would appear the impact of a nutritional intervention of this kind is likely to remain 325 
severely restricted.  326 
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Figure 1: Overview of the NUSTART trial design  476 
Abbreviations: ART, Antiretroviral therapy; LNS, lipid-based nutrient supplement; LNS-VM, LNS 477 
with added vitamin and mineral mix. 478 
 479 
Figure 2: Flow of subsample participants from identification to analysis of iron markers at baseline 480 
and week 6 post-ART. 481 
Abbreviations: ART, antiretroviral therapy; LNS, lipid-based nutritional supplement without added 482 
vitamins and minerals; LNS-VM, lipid-based nutritional supplement with added vitamins and 483 
minerals; BMI, body mass index; sTfR, soluble transferrin receptor. 484 
*Inclusion criteria: >18 years, BMI<18.5 kg/m2, CD4 count<350/µl or stage 3 or 4 AIDS, ART-485 
naïve apart from those who received ART during standard prevention of mother-to-child 486 
transmission regimes, and informed consent. Self-reported pregnancy was an exclusion criterion.  487 
† Note haemoglobin (Hb) and C-reactive protein (CRP) were collected from all patients at 488 
recruitment and 6 weeks post-ART. The flow diagram for the whole sample is published 489 
elsewhere(32) . Available samples at baseline: CRP, n=1762; Hb, n=1670. Available samples at week 490 
6: CRP, n=863; Hb, n=826.   491 
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Table 1: Baseline characteristics of the iron marker subsample by trial arm and overall summaries of those included in and excluded from the iron 
marker sub-sample 









 (LNS control) 
 








N (%)  353 (100) 175  (49.6) 178 (50.4) 1462 (100)  
Site (Lusaka), n (%)  218 (62) 107 (61) 111 (62) 893 (61) 0.82 
Age (years), mean (SD)  36.0 (9.1) 36.4 (9.2) 35.7 (9.1) 35.8 (9.5) 0.67 
Female, n (%)  181 (51) 91 (52) 90 (51) 728 (50) 0.72 
BMI (kg/m2), mean (SD) All 16.4 (1.4) 16.5 (1.3) 16.4 (1.5) 16.5 (1.3) 0.58 
n (%) BMI <16 kg/m2 111 (31) 51 (29) 60 (33) 495 (34) 0.26 
n (%) BMI 16-16.9 kg/m2 103 (29) 56 (32) 47 (26) 365 (25)  
n (%) BMI 17-18.5 kg/m2 139 (39) 68 (39) 71 (40) 602 (41)  
Oedema, n (%)  12 (3) 6 (3.4) 6 (3.3) 54 (4) 0.79 
CD4 count (cells/µl), mean (sd) All 138 (100) 134 (99) 141 (101) 137 (100) 0.86 
Hb (g/L), mean (sd) All 93 (23) 93 (23) 93 (22) 96 (23) 0.012 
Hb group†                               n (%) Severe anaemia 98 (28) 51 (29) 47 (26) 300 (21) 0.011 
n (%) Moderate anaemia 141 (40) 68 (39) 73 (41) 669 (46)  
n (%) Mild anaemia 54 (15) 23 (13) 31 (17) 231 (16)  
n (%) Normal 26 (7) 15 (9) 11 (6) 151 (10)  
n (%) Missing 34 (10) 18 (10) 16 (9) 111 (7)  
Serum CRP (mg/L), median (IQR)  71 (18, 160) 69 (20, 160) 83 (16, 160) 57 (13,155) 0.014 
TB treatment pre-ART, n (%)  99 (28) 49 (28) 50 (28) 352 (24) 0.12 
Using Co-trimoxazole, n(%)  294 (84) 141 (81) 153 (86) 1192 (82) 0.43 
sTfR (nmol/L), mean (SD)  44 (18) 43.2 (17.6) 43.7 (19.0) N/A N/A 
Serum ferritin (µg/L), median (IQR) 752 (288, 1246) 722 (325, 1287) 754 (281, 1200) N/A N/A 
 
 
Abbreviations: LNS-VM, lipid-based nutritional supplement with added vitamins and minerals; LNS, lipid-based nutritional supplement without added vitamins and 
minerals; SD, standard deviation; BMI, body mass index; Hb, haemoglobin; CRP, C-reactive protein; TB, tuberculosis; ART, antiretroviral therapy; sTfR, soluble 
transferrin receptor.  
* Chi-squared test to compare proportions, independent t-tests to compare means of normally distributed data, and the Wilcoxon-Mann-Whitney test to compare 
medians of non-parametric data. 
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† Normal defined as ≥120g/L for women and ≥130g/L for men. Mild anaemia defined as Hb <120g/L for women and <130g/L for men. Moderate and severe 




Table 2: Overview of changes in iron and inflammatory markers from baseline to week 6 by trial arm, unadjusted. 
 
Abbreviations: LNS, lipid-based nutrient supplement; LNS-VM, LNS with added vitamins and minerals; Hb, haemoglobin; CI, confidence interval; sTfR, soluble 
transferrin receptor; CRP, C-reactive protein 
*Only patients with week 6 data included therefore lower sample size than Table 1.  
† Paired t-test 
 
 
 LNS-VM (intervention)  LNS Control 
Variable  N* Baseline Week 6 P value†  N* Baseline Week 6 P value† 
Hb (g/L),  
mean (95% CI) 
383 98 (96, 100) 104 (102, 106) <0.001   369 100 (97, 102) 103 (100, 105) 0.029 
Serum ferritin (µg/l), 
geometric mean (95% CI) 
76 425 (329, 547) 284 (219, 368) 0.004  89 466 (373, 581) 366 (289, 463) 0.021 
sTfR (nmol/L),  
mean (95% CI) 
85 41 (38, 45) 46 (43, 50) 0.030  101 41 (38, 45) 45 (42, 48) 0.045 
Serum CRP (mg/L),  
geometric mean (95% CI) 




Table 3: Linear regression showing the effect of the intervention on haemoglobin, iron and inflammatory markers at week 6 with regression 
coefficients (B), 95% CIs and the corresponding P values, using three models of adjustment.  
  Model 1*  Model 2†  Model 3‡ 
Variable (week 6) N§ B|| 95% CI P 
value¶ 
 B|| 95% CI P 
value¶ 
 B|| 95% CI P 
value¶ 
Hb (g/L) 705 2.16 -0.91, 5.23 0.17  1.88 -1.13, 4.90 0.22  1.60 -1.30, 4.49 0.28 
Log serum ferritin  165 -0.20 -0.50, 0.09 0.18  -0.20 -0.49, 0.09 0.18  -0.19 -0.46, 0.07 0.14 
sTfR (nmol/L) 164 0.99 -3.57, 5.55 0.67  1.02 -3.55, 5.59 0.66  1.68 -2.95, 6.33 0.47 
Log serum CRP  838 -0.10 -0.29, 0.10 0.33      -0.11 -0.29, 0.08 0.26 
 
 
Abbreviations: B, regression coefficient; CI, confidence interval; Hb, haemoglobin; sTfR, soluble transferrin receptor; CRP, C-reactive protein 
*Adjusted for baseline value of the same dependent variable  
†Adjusted for the baseline value of the same dependent variable and log-CRP at week 6 for the iron markers.  
‡Adjusted for the baseline value of the same dependent variable, log-CRP at week 6 for the iron markers, sex, site, age, baseline CD4 count, being on TB medicine at 
recruitment, taking iron supplements in addition to the study supplement, length of time from recruitment to ART and baseline BMI. 
§Number restricted to the same sample as in the fully adjusted Model 3. 
||The coefficient shows the effect associated with the intervention on week 6 outcomes in comparison to the control.  




Table 4: Linear regression models showing the effect of the intervention on iron markers at week 6, stratified by baseline iron marker category* 
Dependent Variable 
(week 6) 
N Baseline iron marker 
category stratification† 
Coefficient‡ 95% CI P value§ P value (test for 
interaction)|| 
Hb (g/L) 705 Normal & mild anaemia 3.31 -1.82, 8.44 0.21 0.38 
Moderate & severe anaemia 0.58 -2.95, 4.10 0.75 
138 Ferritin below median 0.70 -7.56, 8.97 0.87 0.18 
Ferritin above median 8.73 -0.83, 18.28 0.07 
138 sTfR below median 3.59 -5.00,  12.19 0.41 0.61 
sTfR above median 6.64 -2.75, 16.04 0.16 
       
Log Serum ferritin  148 Normal & mild anaemia 0.05 -0.43, 0.54 0.83 0.12 
Moderate & severe anaemia -0.40 -0.74, -0.06 0.023 
165 Ferritin below median -0.08 -0.42, 0.26 0.63 0.30 
Ferritin above median -0.35 -0.76, -0.06 0.10 
165 sTfR below median -0.27 -0.63, 0.09 0.14 0.52 
sTfR above median -0.11 -0.48, 0.26 0.55 
       
sTfR (nmol/L) 147 Normal & mild anaemia 1.77 -6.77, 10.31 0.68 0.60 
Moderate & severe anaemia -0.91 -6.98, 5.17 0.77 
164 Ferritin below median 2.77 -3.05, 8.59 0.35 0.52 
Ferritin above median -0.06 -7.09, 6.97 0.99 
164 sTfR below median 2.74 -3.71, 9.19 0.40 0.59 
sTfR above median 0.32 -6.24, 6.88 0.92 
 
Abbreviations: CI, confidence interval; Hb, haemoglobin; sTfR, soluble transferrin receptor. 
* Adjusted for the baseline value of the same dependent variable, log-CRP at week 6 for the iron markers, sex, site, age, baseline CD4 count, being on TB medicine 
at recruitment, taking iron supplements in addition to the study supplement, length of time from recruitment to ART and baseline BMI. 
†Hb categories defined as normal ≥120g/L for women and ≥130g/L for men, mild anaemia <120g/L for women and <130g/L for men, moderate and severe anaemia 
<110g/L and <80g/L respectively for both sexes. Serum ferritin median = 752µg/l. sTfR median = 45 nmol/L.  
‡The coefficient shows the change in week 6 iron marker associated with the intervention in comparison to the control within the baseline iron marker category 
strata.  
§Two sample t-test  
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||Likelihood ratio test comparing models with and without the interaction between trial arm and baseline iron marker category.
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Table 5: Pairwise correlation matrix between iron markers and CRP at baseline and week 6, unadjusted†‡ 
 




































Log serum CRP, 
baseline 
1.00        
Hb, baseline -0.31** 1.00       
sTfR, baseline -0.10  -0.26** 1.00      
Log serum ferritin, 
baseline 
0.34** -0.02 -0.12* 1.00     
Log serum CRP,  
week 6 
0.30** -0.19** -0.15* 0.24** 1.00    
Hb, week 6 -0.13** 0.51** -0.10 0.11  -0.26** 1.00   
sTfR, week 6 -0.10  -0.14 0.32** -0.31** 0.00  -0.27** 1.00  
Log serum ferritin, 
week 6 
0.16* 0.20* -0.07 0.54** 0.24** 0.16* -0.22** 1.00 
 
Abbreviations: CRP, C-reactive protein; Hb, haemoglobin; sTfR, soluble transferrin receptor 
† Pearson’s correlation.  
‡ N: serum CRP baseline (1762), Hb baseline (1670), sTfR baseline (353), serum ferritin baseline (353), serum CRP week 6 (863), Hb week 6 (826), sTfR week 6 
(186), serum ferritin week 6 (165). Note that CRP and Hb were available for the whole trial sample, sTfR and ferritin only for the the subsample, and sample sizes 







Table 6: Multivariable linear regression model showing the effect of a one-log decrease in CRP on change in iron markers from baseline to week 6* 
Variable (change from 
baseline to week 6) 
N Coefficient† 95% CI P value‡ 
Hb (g/L) 687 1.81 0.85, 2.76 <0.001 
Log serum ferritin 165 -0.11 -0.20, 0.03 0.012 
sTfR (nmol/L) 164 -0.24 -1.89, 1.42 0.78 
 
Abbreviations: CI, confidence interval; Hb, haemoglobin; sTfR, soluble transferrin receptor. 
*Adjusted for trial arm, sex, site, age, baseline CD4 count, being on TB medicine at recruitment, taking iron supplements in addition to the study supplement, length 
of time from recruitment to ART and baseline BMI. 
†The coefficient represents the change in iron marker from baseline to week 6 associated with a one-log decrease in CRP from baseline to week 6.  
‡Two sample t-test score result. 
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